ISS backs Dynavax directors in board fight with Deep Track Capital

Institutional Shareholder Services (ISS) has recommended that Dynavax Technologies shareholders reelect all current company directors, opposing Deep Track Capital's nominees in an upcoming vote on June 11. ISS stated that Deep Track Capital, Dynavax's second-largest shareholder with a 15% stake, failed to make a compelling case for change, despite acknowledging a recent stall in momentum for Dynavax, whose stock has fallen 18% in the last year. Deep Track is advocating for a focus on the Heplisav hepatitis B vaccine and a halt to new acquisitions.

Analysis

Dynavax Technologies (DVAX) has received a significant endorsement from Institutional Shareholder Services (ISS), which recommended shareholders reelect all incumbent directors, thereby opposing the four nominees proposed by activist investor Deep Track Capital. Deep Track Capital, Dynavax's second-largest shareholder with a considerable c.15% stake, has been advocating for a strategic pivot, urging the company to focus exclusively on the development and growth of its hepatitis B vaccine, Heplisav, and to halt new acquisitions, positioning Dynavax as an attractive asset for a larger pharmaceutical acquirer. Despite ISS acknowledging a recent "stall in momentum" for Dynavax, which has seen its stock price decline by 18% over the last 12 months, the influential proxy advisory firm concluded that Deep Track "failed to present a compelling case that change is necessary at this meeting," further noting that "the market has in no way rebuked the company's strategy." This recommendation is pivotal as ISS guidance often shapes shareholder voting patterns, potentially reinforcing the current management's standing and strategic approach ahead of the June 11 investor vote.

Key Decisions for Investors

• The ISS recommendation significantly bolsters the current board's position against Deep Track Capital's challenge, reducing the immediate probability of a forced strategic overhaul focused solely on Heplisav.
• Investors should monitor the June 11 shareholder vote outcome, as substantial support for Deep Track's nominees, even if unsuccessful, could still pressure management to address the acknowledged 'stall in momentum' and the 18% stock price decline.
• Consider the company's forward strategy in light of ISS's backing, particularly how management plans to address the underlying performance concerns and drive value beyond the current Heplisav trajectory, given the likely continuation of their broader strategic initiatives including potential acquisitions.